GlassScriptPhysician profile
Ashutosh V Bapat
NPI 1669525812
$3,861.80
in general payments reported to CMS, 2019-2025
20 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $156 · 2021: $54.05 · 2022: $306 · 2023: $763 · 2024: $859 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $852.20 | 2019 | |
| Medtronic, INC. | $737.77 | 2022-2025 | Resolute Onyx |
| Boston Scientific Corporation | $608.72 | 2019-2025 | Watchman Access System, Watchman, Watchman Flx |
| Medtronic Vascular, INC. | $365.34 | 2019-2020 | |
| Edwards Lifesciences Corporation | $341.21 | 2019-2024 | Evoque, Pascal |
| E.R. Squibb & Sons, L.L.C. | $168.83 | 2023-2025 | Eliquis, Camzyos |
| Siemens Medical Solutions USA, INC. | $142.70 | 2020-2024 | Acuson Origin Diagnostic Ultrasound System |
| Philips North America LLC | $131.99 | 2021-2024 | (Ao0) Igt Devices Intracardiac |
| Amgen INC. | $96.34 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.12 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.10 | 2023-2025 | Lifevest |
| Ancora Heart, INC. | $54.16 | 2024-2025 | Accucinch |
| Novo Nordisk INC | $52.13 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $30.66 | 2023-2025 | Verquvo |
| Irhythm Technologies, INC. | $30.43 | 2024 | Zio Xt Patch, Zio Monitor |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.65 | 2023-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $18.99 | 2023 | |
| Astellas Pharma US INC | $18.23 | 2023 | Lexiscan |
| Pfizer INC. | $14.43 | 2023 | |
| Scpharmaceuticals INC. | $13.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashutosh Bapat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.